DexCom, Inc. (NASDAQ:DXCM) Stock Position Trimmed by Hollencrest Capital Management

Hollencrest Capital Management reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 38.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,000 shares of the medical device company’s stock after selling 620 shares during the quarter. Hollencrest Capital Management’s holdings in DexCom were worth $113,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Gilbert & Cook Inc. boosted its holdings in shares of DexCom by 8.2% in the fourth quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock valued at $426,000 after acquiring an additional 261 shares in the last quarter. 9258 Wealth Management LLC acquired a new position in shares of DexCom during the 4th quarter valued at $286,000. Dimensional Fund Advisors LP increased its position in shares of DexCom by 6.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 647,172 shares of the medical device company’s stock valued at $80,308,000 after purchasing an additional 39,786 shares during the period. Avantax Advisory Services Inc. bought a new stake in shares of DexCom in the 4th quarter worth $330,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of DexCom in the fourth quarter valued at $284,000. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders sold 2,483 shares of company stock valued at $201,708 in the last quarter. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Redburn Atlantic assumed coverage on DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Morgan Stanley dropped their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Oppenheimer reduced their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, July 26th. BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Finally, Royal Bank of Canada cut their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $112.25.

DexCom Trading Down 2.1 %

Shares of NASDAQ DXCM opened at $70.43 on Friday. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The business has a 50-day moving average price of $78.19 and a two-hundred day moving average price of $109.63. The firm has a market capitalization of $28.01 billion, a PE ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the company posted $0.34 earnings per share. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. As a group, analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.